<DOC>
	<DOC>NCT02524444</DOC>
	<brief_summary>Randomized controlled single blind prospective comparative study.</brief_summary>
	<brief_title>A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients</brief_title>
	<detailed_description>This study is intended to be a randomized controlled single blind prospective comparative study conducted to compare the efficacy of three, monthly doses of sulphadoxine-pyrimethamine as intermittent preventive therapy with Mefloquine as-intermittent preventive therapy in HIV-infected pregnant women.</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Pregnant HIV positive patients Gestational age 16 weeks and above No history of use of Mefloquine or Sulphadoxine Pyrimethamine four weeks prior to recruitment. Anaemia packed cell volume less than 30% Pre existing medical conditions Diabetes Mellitus, Hypertension Allergy to Sulphadoxine Pyrimethamine or Mefloquine Nonconsenting patients Multiple gestation Known psychiatric illness Known seizure disorder History of severe renal or hepatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Intermittent preventive therapy</keyword>
	<keyword>malaria</keyword>
	<keyword>pregnant</keyword>
	<keyword>HIV positive</keyword>
	<keyword>Prevention</keyword>
</DOC>